Abstract
Despite the lack of randomized and prospective studies the benefit of MC therapy can not be attributed merely to patient selection, since substantial increase of survival time and long term survivors are seen only in patients who have received, and responded to treatment. In the absence of factors predicting the therapeutic response, all patients with overt MC should be treated with the possible exception of these with widespread and uncontrolled systemic neoplasia. The respective weight of systemic and intraventricular chemotherapy, and radiation therapy, remains unclear. It may depend upon the stage and the nature of the primary neoplasia. When intraventricular MTX is used, monitoring of drug concentrations is advised.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
